We are live on ! Find out more

Alpha Teknova

TKNO

Market cap $372M

6.92 USD

-0.32

4.42%

At close Updated Sep 4, 4:00 PM EDT

Pre-market

After hours

6.90

-0.02

0.29%

1 day

-4.42%

5 days

-3.22%

1 month

25.36%

3 months

27.44%

6 months

195.73%

Year to date

77.44%

1 year

63.21%

5 years

-66.55%

10 years

-72.32%

About: Alpha Teknova Inc is a producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. Its offer two primary product categories: Lab Essentials and Clinical Solutions. It derives key revenue from the United States. The company offers three primary product types: (i) pre-poured media plates for cell growth and cloning; (ii) liquid microbial culture media and supplements for cellular expansion; and (iii) molecular biology reagents for sample manipulation, resuspension, and purification.

Employees: 158

Healthcare Drug Manufacturers - Specialty & Generic

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 55.6%

Neutral 44.4%

Negative 0%

Alpha Teknova Raises Outlook After Record Q2 Revenue at Sidoti Conference

Alpha Teknova NASDAQ: TKNO Chief Financial Officer Matt Lowell said the provider of laboratory and bioprocessing reagents is seeing renewed growth, reporting record second-quarter revenue and raising its full-year outlook as biopharma funding and life-science end markets improve.

Alpha Teknova Raises Outlook After Record Q2 Revenue at Sidoti Conference

Zacks Investment Research

Alpha Teknova (TKNO) is a Great Momentum Stock: Should You Buy?

Does Alpha Teknova (TKNO) have what it takes to be a top stock pick for momentum investors? Let's find out.

Alpha Teknova (TKNO) is a Great Momentum Stock: Should You Buy?

Zacks Investment Research

Wall Street Analysts Believe Alpha Teknova (TKNO) Could Rally 35.45%: Here's is How to Trade

The mean of analysts' price targets for Alpha Teknova (TKNO) points to a 35.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Believe Alpha Teknova (TKNO) Could Rally 35.45%: Here's is How to Trade

Alpha Teknova Q2 Earnings Call Highlights

Alpha Teknova NASDAQ: TKNO reported second-quarter revenue growth of 18% from a year earlier, surpassing $12 million for its highest quarterly revenue in the company's 30-year history. The company raised its full-year revenue outlook, citing first-half performance and confidence in the second half of 2026.

Alpha Teknova Q2 Earnings Call Highlights

Alpha Teknova, Inc. (TKNO) Q2 2026 Earnings Call Transcript

Alpha Teknova, Inc. (TKNO) Q2 2026 Earnings Call Transcript

Alpha Teknova, Inc. (TKNO) Q2 2026 Earnings Call Transcript

Teknova Reports Second Quarter 2026 Financial Results

Second quarter 2026 total revenue was $12.2 million, up 18% over the same quarter prior year Company raises 2026 revenue guidance to $45-47 million Launched proprietary AI-powered Build-Tek™ custom order configurator, giving developers a faster path from preclinical to clinical manufacturing HOLLISTER, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the second quarter ended June 30, 2026.

Teknova Reports Second Quarter 2026 Financial Results

Teknova Launches Build-Tek™, a Proprietary AI Reagent Assistant That Allows Customers to Configure Complex Custom Product Requests in Minutes

HOLLISTER, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today launched Build-Tek™, an AI-powered custom order configurator that enables developers of therapies and diagnostics to design complex custom products and submit a request for quote in minutes.

Teknova Launches Build-Tek™, a Proprietary AI Reagent Assistant That Allows Customers to Configure Complex Custom Product Requests in Minutes

Conestoga Micro Cap Composite Q2 2026 Leaders, Laggards, Buys And Sells

Revenue increased 19% year-over-year, reinforcing confidence that TWST's technology leadership and expanding product portfolio continue to drive market share gains. We continue to believe AORT's expanding aortic portfolio and product pipeline provide meaningful long-term growth opportunities. We remain encouraged by PLMR's disciplined underwriting approach, diversified specialty portfolio, and ability to historically deploy capital into attractive growth opportunities.

Conestoga Micro Cap Composite Q2 2026 Leaders, Laggards, Buys And Sells

Teknova to Report Second Quarter 2026 Financial Results on August 5, 2026

HOLLISTER, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the second quarter ended June 30, 2026, on Wednesday, August 5, 2026, following the close of market.

Teknova to Report Second Quarter 2026 Financial Results on August 5, 2026

Alpha Teknova, Inc. (TKNO) Q1 2026 Earnings Call Transcript

Alpha Teknova, Inc. (TKNO) Q1 2026 Earnings Call Transcript

Alpha Teknova, Inc. (TKNO) Q1 2026 Earnings Call Transcript

See News Rankings

Price charts implemented using Lightweight Charts™